



Restriction Map of pTet-On-Advanced Vector. Unique restriction sites are in bold

Description

pTet-On-Advanced expresses an improved version of the reverse Tet (tetracycline)-controlled transactivator protein (rtTA), called rtTA-Advanced (1–4). It is more sensitive to doxycycline (Dox) and yields lower background expression than the original rtTA used in the Tet-On[®] System (2). The rtTA-Advanced protein is a fusion of amino acids 1–207 of a mutant Tet repressor (TetR) and 39 amino acids containing three minimal "F"-type transcriptional activation domains from the VP16 protein of herpes simplex virus. It is fully synthetic, lacks cryptic splice sites, and is codon-optimized for stable expression in mammalian cells.

Use

The pTet-On-Advanced Vector is used to develop stable Tet-On Advanced cell lines, which are hosts for a Dox-induced gene expression system. Once a vector containing a gene of interest under control of a Tet-responsive element (e.g., TRE-Tight or TRE2) is transfected into a Tet-On Advanced cell line, rtTA-Advanced binds to the TRE, and activates transcription of the gene of interest in the presence of Dox in a highly dose-dependent manner. Additional information on TRE-containing vectors and protocols describing the construction of Tet-On Advanced cell lines can be found in the Tet-On Advanced Inducible Gene Expression System User Manual (PT3898-1).



Clontech

United States/Canada
800.662.2566

Asia Pacific
+1.650.919.7300

Europe
+33.(0)1.3904.6880

Japan
+81.(0)77.543.6116

Clontech Laboratories, Inc.
A Takara Bio Company
1290 Terra Bella Ave.
Mountain View, CA 94043
Technical Support (US)
E-mail: tech@clontech.com
www.clontech.com

(PR742221; published 11 April 2007)

Location of Features

- Fragment containing P_{CMV} : 86–677
- rtTA-Advanced: 775–1521
- Fragment containing the SV40 poly A signal: 1544–1977
- Col E1 origin of replication: 2344–2987
- Ampicillin resistance gene:
 β -lactamase coding sequences: 3994–3134
- Neomycin/kanamycin resistance gene: 6201–5407
- SV40 promoter (P_{SV40}) controlling expression of the neomycin/kanamycin resistance gene: 6865–6522.

Propagation in *E. coli*

- Suitable host strains: DH5 α and other general purpose strains.
- Selectable marker: plasmid confers resistance to ampicillin (100 μ g/ml) in *E. coli* hosts.
- *E. coli* replication origin: Col E1

References

1. Tet-On Advanced Inducible Gene Expression System (July 2006) *Clontechiques* **XXII**(2):1–3.
2. Urlinger, S., *et al.* (2000) *Proc. Natl. Acad. Sci. USA* **97**(14):7963–7968.
3. Gossen, M. & Bujard, H. (1992) *Proc. Natl. Acad. Sci. USA* **89**(12):5547–5551.
4. Gossen, M., *et al.* (1995) *Science* **268**(5218):1766–1769.

Note: The attached sequence file has been compiled from information in the sequence databases, published literature, and other sources, together with partial sequences obtained by Clontech. This vector has not been completely sequenced.

Notice to Purchaser

Clontech products are to be used for research purposes only. They may not be used for any other purpose, including, but not limited to, use in drugs, in vitro diagnostic purposes, therapeutics, or in humans. Clontech products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without written approval of Clontech Laboratories, Inc.

Use of the Tetracycline controllable expression systems (the "Tet Technology") is covered by a series of patents including U.S. patents # 5,464,758 and #5,814,618, which are proprietary to TET Systems Holding GmbH & Co. KG. Academic research institutions are granted an automatic license with the purchase of this product to use the Tet Technology only for internal, academic research purposes, which license specifically excludes the right to sell, or otherwise transfer, the Tet Technology or its component parts to third parties. Notwithstanding the above, academic and not-for profit research institutions whose research using the Tet Technology is sponsored by for profit organizations, which shall receive ownership to all data and results stemming from the sponsored research, shall need a commercial license agreement from IP Merchandisers in order to use the Tet Technology. In accepting this license, all users acknowledge that the Tet Technology is experimental in nature. TET Systems Holding GmbH & Co. KG makes no warranties, express or implied or of any kind, and hereby disclaims any warranties, representations, or guarantees of any kind as to the Tet Technology, patents, or products. All others are invited to request a license from TET Systems Holding GmbH & Co. KG prior to purchasing these reagents or using them for any purpose. Clontech is required by its licensing agreement to submit a report of all purchasers of the Tet-controllable expression system to IP Merchandisers, Inc.

For license information, please contact:

Hans Peter Kneubuehl

TET Systems Holding GmbH & Co.
KG Im Neuenheimer Feld 582 69120 Heidelberg Germany
Tel +49 6221 588 04 00 Fax +49 6221 588 04 04
eMail: kneubuehl@tet-systems.de

or use our electronic licensing request form via http://www.tetsystems.com/main_inquiry.htm

The CMV promoter is covered under U.S. Patent Nos. 5,168,062 and 5,385,839 assigned to the University of Iowa Research Foundation.

Clontech, the Clontech logo and all other trademarks are the property of Clontech Laboratories, Inc., unless noted otherwise. Clontech is a Takara Bio Company. ©2007